Delix Therapeutics
Non-hallucinogenic psychedelic-derived neuroplastogens (zalsupindole for depression)
Delix Therapeutics (Boston, United States) — non-hallucinogenic psychedelic-derived neuroplastogens (zalsupindole for depression). On November 9, 2026 it announced a $100M Series C, led by Johnson & Johnson Innovation (JJDC), SV Health Investors' Dementia Discovery Fund. Oversubscribed. Funds take zalsupindole (DLX001) into Phase II. Prior: $70M Series A (2021).
Biotech
📍 Boston
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Delix Therapeutics going public?
No. Delix Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Delix Therapeutics' valuation in 2026?
No confirmed valuation is on record for Delix Therapeutics. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Delix Therapeutics filed an S-1?
No public S-1 is on file for Delix Therapeutics.
Who are Delix Therapeutics' investors?
Delix Therapeutics' investors include Johnson & Johnson Innovation (JJDC), SV Health Investors' Dementia Discovery Fund, OMX Ventures, RA Capital Management, Artis Ventures, UC Investments and 1 more.
How much has Delix Therapeutics raised?
Delix Therapeutics has raised $170M in total across 1 disclosed round, most recently a Series C of $100M in Nov 2026.
Is Delix Therapeutics publicly traded — can you buy Delix Therapeutics stock?
No. Delix Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Delix Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Last Round
Series C — $100M (Nov 2026) · Lead: Johnson & Johnson Innovation (JJDC) / SV Health Investors' Dementia Discovery Fund
Fundraising Status
Series C · $100M · this month
privateTotal raised $170M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series C | $100M | Nov 2026 | Johnson & Johnson Innovation (JJDC) / SV Health Investors' Dementia Discovery Fund | — |
Recent Activity
💰Nov 2026 · Fierce Biotech · funding
Vertical Intelligence — Biotech / Gene Therapy
Biotech / Gene Therapy registry data for Delix Therapeutics has not been collected yet — the weekly vertical sweep hasn't reached this company. Check back soon.
Talent Signal
Hiring data for Delix Therapeutics has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Investors
Johnson & Johnson Innovation (JJDC) · SV Health Investors' Dementia Discovery Fund · OMX Ventures · RA Capital Management · Artis Ventures · UC Investments · Dolby Family Ventures
BiotechNon-hallucinogenic neuroplastogens
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.